Attendee search 

NanoTech Pharma focus on nanomedicine formulation development, located in New Jersey USA since year 2018. We have rich experiences in liposome and nanocrystal drug delivery systems. Our pipelines include 2 ANDA and several 505(b)(2) drugs, some of which have filed patents and are moving up to commercial scale.

Wuxi Biocity is a biopharmaceutical company mainly focusing on discovery, development, clinical trials and commercialization of "Best-in-Class" and "First-in-Class" original new drug of oncology and autoimmune diseases. Established in December 2017 in Wuxi, Biocity aims to benefit patients around the world as a pioneer pharmaceutical company in China with sustainable innovation ability and therapeutic products. With the noble mission of "Better Medicine for Better Life", our team always adhere to scientific evidence, while consider unfulfilled medical needs ahead of time, to achieve the goal of patient-centered, full-lifecycle disease management. Biocity's programs successfully entered into clinical stages within three years of efficient operation.



We are honored to have domestic and international academicians, well-known scientists, enterprise and policy specialists, clinical experts in particular, on our advisory board to guide Biocity's scientific, clinical, and strategic development. To reach our long-term goal of sustainable competitive advantages, we collaborate with the Wuxi government on multiple aspects to establish the "Biocity Innovation Institute for Translational Medicine". Thus we can further dig into the translational medical research from the discovery of disease mechanisms to the therapeutic applications of certain scientific achievements. Biocity Innovation Institute will strengthen our R&D ability and innovation capacity, therefore accelerate the popularization and enhancement of translational medicine in Wuxi, Jiangsu.



We have been recognized by many investment firms and intend to conduct an IPO in the very near future. With great efforts, we will bring safe and effective local innovative medicine at the best of times, to meet the increasing medical needs globally.

以尖端生命科学技术转化为核心，专注于ReproCore超微因子系列生物制品的研发、生产、销售、服务为主营业务，涉及医学康养、医学美容、健康调理、精准医疗等领域，以严谨的科学态度、严格的技术标准、完备的质量保障、一流的产品服务，致力于为广大消费者，特别是社会高端人群打造全生命周期的个性化健康定制咨询、产品、服务、管理于一体的健康生态平台。

We are a group of angels selecting top companies to invest.

Big Pharma

华润集团一级利润中心，聚焦生命科学领域投资与合作

Approximately 900,000 people annually in the United States suffer from damage to the articular cartilage and subchondral bone, with the knee being the most commonly affected. Articular cartilage lesions have a limited intrinsic ability to heal and often result in osteoarthritis (OA). Progression to OA poses significant economic burden for the United States, totaling over $300 billion annually, and negatively impacting 54.4 million adults (23% of the population). Current strategies for cartilage restoration include bone marrow stimulation (microfracture) and autologous chondrocyte implantation (ACI). These methods have high failure rates (25-50% at 10 years), prolonged rehabilitation times (> 12 months), and show decreasing efficacy in patients older than 40-50 years of age. 

Sparta Biomedical is developing the first-of-its kind osteochondral repair technology (SBM-01) for support the restoration of the cartilage-bone unit. This purpose-built technology is comprised of a novel biomimetic material possesses cartilage-like properties-- tension, compression, tribology, and fatigue.  The patent-pending surface is combined with a uniquely designed base to promote efficient osseous attachment and stable fixation over the long-term. Sparta’s technology will be a significant advancement in the current surgical standard of care. It will result in substantial pain reduction, immediate weight bearing post-operatively, and full range ambulation.

Sparta has assembled a nationally recognized team of scientists, clinicians, orthopedic regulatory experts to develop SBM-01 rapidly and cost effectively. SBM-01's risk profile enables an efficient regulatory path. Furthermore, it is well positioned to obtain Breakthrough Device Designation from the US FDA.

AlephBot is developing a new paradigm in healthcare, the procedure monitor.
The solution helps medical teams maximize treatment efficiency during and after medical procedures (e.g., resuscitation, labor, general anesthesia). It provides the team members with valuable real-time information that is adaptive to their actions and to the procedure’s stage, even if they are under pressure or can’t recall procedure steps by heart. AlephBot also automatically documents the medical procedure, which serves for both medical education and medico-legal purposes.

** AlephBot uniqueness **
We capture the human perspective of a procedure by analyzing the relevant info from the on-going structural medical conversation. We add this layer to the data collected from other sources.
Therefore, we gain higher accuracy of the analyzed medical situation, which enables us to identify the procedure stage and provide meaningful info, in real-time.

** Status **
AlephBot is developing its core technology. The company, pre-seed funded, was selected to the DRIVE accelerator at the Technion (Israel institute of Technology), and received grants from the Israel Innovation Authority.
AlephBot cooperates with big and small hospitals from day one. This serves our intention to increase treatment efficiency both in mega-hospitals in big cities and in smaller ones in the periphery and rural areas.

AlephBot is active in its target markets (Germany, France, Italy and the US) and won several national and international (France, Germany, Denmark) events and competitions. The company is still not active in China - an opportunity!

** Next steps **
We are currently looking for seed investment to finalize our core technology development and bring the product to clinical trial stage in two years. Sales are planned in three years, post regulation clearance.

Genetron